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Abstract
Background: As part of a formal evaluation of the Quantiferon-Gold in-tube assay (QFT-IT) for latent TB infection we
compared its sensitivity to the tuberculin skin test (TST) in confirmed adult TB cases in Indonesia. Smear-positive TB disease
was used as a proxy gold standard for latent TB infection.
Methods and Findings: We compared the sensitivity of QFT-IT and TST in 98 sputum smear and chest x-ray positive TB
cases and investigated risk factors for negative and discordant results in both tests. Both tests showed high sensitivity; (QFT-
IT; 88.7%: TST; 94.9%), not significantly different from each other (p value 0.11). Very high sensitivity was seen when tests
were combined (98.9%). There were no variables significantly associated with discordant results or with a negative TST. For
QFT-IT which particular staff member collected blood was significantly associated with test positivity (p value 0.01). Study
limitations include small sample size and lack of culture confirmation or HIV test results.
Conclusions: The QFT-IT has similar sensitivity in Indonesian TB cases as in other locations. However, QFT-IT, like the TST
cannot distinguish active TB disease from LTBI. In countries such as Indonesia, with high background rates of LTBI, test
specificity for TB disease will likely be low. While our study was not designed to evaluate the QFT-IT in the diagnosis of
active TB disease in TB suspects, the data suggest that a combination of TST and QFT-IT may prove useful for ruling out TB
disease. Further research is required to explore the clinical role of QFT-IT in combination with other TB diagnostic tests.
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Introduction
Tuberculosis (TB) remains a problem worldwide and, despite
significant efforts, mortality and incidence rates remain alarmingly
high [1]. Treatment of latent TB Infection (LTBI) has been shown
to be an effective and safe method of preventing progression to
disease in infected individuals following screening and will need to
be part of a TB elimination strategy [2,3]. Diagnosis of LTBI has
historically been by the tuberculin skin test (TST), a test with well-
known limitations [4]. Subsequently many developed countries now
employ the newly developed Interferon Gamma Release Assays
(IGRAs) that show superior sensitivity and specificity for LTBI
when compared to the TST [5]. IGRAs evaluate cell-mediated
immunity in vitro through the detection of interferon-c released by
TB antigen stimulated T cells [5,6]. Two such assays are
commercially available, QuantiFERON-TB Gold in-tube test
(QFT-IT) (QFT-IT test; Cellestis Ltd, Carnegie, Australia) and T-
SPOT.TB test (Oxford Immunotec, Abingdon, UK). The QTF-IT
includes three antigens, early-secreted antigen target 6 (ESAT-6),
culture filtrate protein 10 (CFP-10) and TB7.7, which are absent
from all BCG strains and most non-pathogenic mycobacteria [7].
Comparing these tests remains a challenge in the absence of a gold
standard. However test performance can be assessed indirectly by
employing a gradient of exposure or by using active TB as a proxy
formeasuringsensitivitytoLTBI [8,9].Theutilityoftheseassaysfor
LTBI diagnosis remain unknown in Indonesia, a country that has
the third highest caseload of TB disease in the world [10]. As part of
a wider series of studies to indicate performance in the diagnosis of
LTBI, we evaluated the sensitivity of a new generation IGRA;
QFT-IT in comparison with the TST in newly diagnosed sputum
smear positive adult TB cases in Indonesia.
Methods
Ethics statement
This study was approved by the Lower South Island ethical
committee, New Zealand and the Health Research Unit Ethical
Committee University of Padjadjaran, Bandung, Indonesia. QFT-
IT kits were donated by Cellestis Australia.
Study setting and recruitment
Between April 2009 and March 2010 consecutive new TB cases
presenting at a community lung clinic in Bandung, Indonesia were
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sputum smear positive; had radiographic evidence of TB[11] and
had taken medication for # one week. Following written informed
consent from all participants, demographic and clinical data were
collected.
Procedures
Venous blood was obtained and immediately transferred into
the QFT-IT assay kit tubes (nil, mitogen and antigen), vigorously
hand shaken then transferred within two hours to a 37uC
incubator for 16–24 hours. Incubated samples were centrifuged
and stored at 4uC until 28 samples had been collected to allow for
batch processing or up until one month after blood collection. The
QFT-IT assay was conducted according to the manufacturer’s
instructions (QFT; Cellestis, Carnegie, Australia). Optical densities
were measured using a BiotechH microplate reader and GentecH
software, version 1.08 then imported into QFT-IT specific
software (QuantiFERONH-TB Gold analysis software version
2.50.4). Results were interpreted as specified by the manufacturer
(QFT; Cellestis, Carnegie, Australia). Immediately after the
sample for QFT-IT was drawn a TST was performed by an
experienced study nurse on the volar side of the forearm using 2
tuberculin units of purified protein derivative (PPD RT23
BiofarmaH Bandung). Induration was measured after 48–72 hrs.
A positive result was regarded as $10 mm of induration. HIV
status was unable to be obtained as testing is not routinely offered
to the study population.
Statistical analysis
Sensitivity with 95% confidence intervals was estimated for each
diagnostic test using STATA version 11.0. Factors associated with
discordant and false negative results for both tests were identified
using bi-variate regression. Test concordance and discordance
were estimated using the kappa statistic and McNemar’s test
respectively.
Results
Of 152 eligible TB cases 99 (65%) were recruited. The main
reason for non-participation was failure to return to the clinic for
the study, n=30 (60%); the next most common reason was that
the clinic was considered by the patient too far to return to, n=4
(8%). Data from one participant were excluded, as he did not
receive a TST. Nearly half the patients had 3+ sputum smear
status (Table 1). For the QFT-IT 86 patients were positive, 11
(11.2%) were negative and 1 (1%) was indeterminate (Table 2).
Excluding indeterminate results the QFT-IT had a sensitivity of
88.7% (95% CI 80.6% –94.2%). If indeterminate results were
included the sensitivity was 87.8% (95% CI 79.6% –93.5%).
There were 93 TST positive patients (sensitivity 94.9%; 95% CI
88.5% –98.3%). The difference between the sensitivity of each test
was not significant (p value 0.11). Excluding indeterminate QFT-
IT results, both tests were positive in 84.5%, both negative in
1.0%, QFT-IT positive TST negative in 4.1% and QFT-IT
negative TST positive in 10.3% (Table 2). Test agreement was
85.6% (Kappa=0.06; p value 0.27). Discordance was not
significant (p value 0.18). A combination of tests gave a sensitivity
of 98.9% (97 of 98).
There were no differences between patients with TST +/QFT-
IT - or TST -/QFT-IT + and those with concordant results
according to age, sex, ethnicity, presence of a BCG scar, duration
of productive cough, sputum smear status and days on treatment
with anti-tuberculosis medication (data not shown). For QFT-IT
there were no significant differences between groups (true positive
vs. false positive results) regarding age, sex, ethnicity, presence of a
BCG scar, sputum smear status, duration of symptoms or duration
of treatment with anti tuberculosis medication (data not shown).
However, test results varied by study nurse; positive test results for
each of the three nurses were 16/22 (72.7%), 4/4(100%) and 66/
72 (91.6%) respectively; the difference between nurse 1 and 3 of
almost 20% was statistically significant (p value 0.01). For the TST
no significant differences between those patients who were true
positives and those who were false negatives were seen.
Discussion
In 98 patients with sputum smear confirmed TB, employed as a
proxy for LTBI, both the TST and QFT-IT tests displayed high
sensitivity (94.9% and 88.7% respectively). A combination of both
tests yielded a sensitivity of 98.9%. Our findings show slightly
higher sensitivity for both tests than most reports from other
developing, high TB burden countries. Among 60 microbiologi-
cally confirmed TB patients in India 44 (73%) were positive by
QFT-IT [12], in The Gambia of 80 TB culture positive patients
64% were positive by QFT-IT [13] and in South Africa among
131 culture positive TB patients 76% were positive by QFT-IT
[8]. It is unlikely that differences are due to varying HIV
Table 1. Patient characteristics.
Characteristic Number (%)
Age (years):
Median (Range) 31.0 (15–62)
Sex:
Female 53 (54.1)
Ethnicity:
Sundanese 87 (88.8)
Time on anti-tuberculosis medication (days)
Median (Range) 5.0 (1–7)
BCG Scar present:
No 38 (38.8)
Yes 52 (53.1)
Unknown 8 (8.2)
Sputum smear status:
Three plus 43 (43.9)
Two Plus 21 (21.4)
One Plus 32 (33.3)
doi:10.1371/journal.pone.0012020.t001
Table 2. Comparison of results for QFT-IT and TST for sputum
smear positive pulmonary TB cases.
TST result
Quantiferon Result Positive Negative Total
Positive 82 4 86
Negative 10 1 11
Indeterminate 1 0 1
Total 93 5 98
doi:10.1371/journal.pone.0012020.t002
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differences in health seeking behaviour patterns and study
populations[5]: subjects in this study were identified at a
community-based clinic and we did not include retreatment or
treatment failure patients. TB patients who present relatively early,
and with an uncomplicated history, may have less severe disease
and less anergy [5].
Interestingly, our data suggest that false negative results from
the QFT-IT may be due to procedural issues, as we found negative
results to be associated with sample collection personnel. Upon
further investigation with personnel we believe that the most likely
reason for this difference is how vigorously tubes were shaken. It
has previously been shown that levels of shaking vigour affect
results [14]. It appeared from observation that nurse 3 tended to
shake the tubes more vigorously. A further possibility is differing
times to incubation. Recently Herrera et al reported that time to
incubation may be a determinant of indeterminate QFT-IT results
[15]. However, in this study, all samples were incubated within
two hours of collection. The impact of sample collection procedure
on QFT-IT results requires further, focused investigation. This
study had a much lower rate of indeterminate results for QFT-IT
(n=1, 1%) than other studies [7,16,17,18], which may also be
related to processing issues [15]. An emphasis on proper staff
training when using this test and prompt incubation is advisable.
This study employed sputum smear positive patients as a proxy
for LTBI in lieu of a gold standard, QFT-IT, like the TST cannot
distinguish active TB disease from LTBI. In countries such as
Indonesia, with high background rates of LTBI, test specificity for
TB disease is low [19].Our study was not designed to evaluate the
QFT-IT in the diagnosis of active TB disease in TB suspects [17].
However, a combination of TST and QFT-IT may prove useful
for ruling out TB disease in some individuals. Further research is
required to explore the potential of QFT-IT in combination with
other TB diagnostic tests.
With respect to study limitations, we were not able to measure
the effect of HIV on test sensitivity, although HIV prevalence
within the clinic population is below 2% [20]. Also, despite a
relatively large sample size in relation to sensitivity evaluation, our
study was probably too small to identify factors important for
predicting false negative and discordant test results.
Conclusion
The QFT-IT is not more sensitive than the TST for detecting
active TB in this setting. A combination of QFT-IT and TST
offers a sensitivity gain, with further studies required to show
whether there is an associated significant specificity loss. Further
evaluation of the QFT-IT in Indonesia will assess its performance
in child TB case contacts against a gradient of exposure and
longitudinal assessment of conversion and reversion rates.
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